Special Issue

Epigenetic Mechanisms of Environmental Diseases

Message from the Guest Editors

This Special Issue, “Epigenetic Mechanisms of Environmental Diseases” will mainly focus on environmental influences on human health. The human genome encodes approximately 30,000 genes. It is estimated that over 8,000 human diseases are caused by defects in single genes. These unifactorial or monogenic diseases are individually rare and affect approximately one percent of the human population. In contrast, complex human diseases such as cancer and type 2 diabetes are believed to involve both susceptibility genes and their interactions with the environment. Gene-environment interactions are thought to be mediated by epigenetic modifications across the genome that represent orchestrated phenomena which modulate the transcriptional output of the genetic code. In this sense, identifying the aberrant changes in the epigenetic landscape associated with environmental diseases such as type 2 diabetes, obesity, cancer and cardiovascular, neurodegenerative and immunological diseases could provide the potential for new approaches for disease prevention and intervention.

Guest Editors

Dr. Paola Ungaro

Istituto per l’Endocrinologia ed l’Oncologia Sperimentale 'G. Salvatore',Consiglio Nazionale delle Ricerche, Napoli, Italy

Dr. Raffaele Teperino

Head of the Environmental Epigenetics Group, Institute of Experimental Genetics, Helmholtz Zentrum München GmbH, Neuherberg, Germany

Deadline for manuscript submissions

closed (31 July 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/78586

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).